Literature DB >> 9151822

Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope.

G Pancino1, P Sonigo.   

Abstract

In lentiviruses, including human immunodeficiency virus and feline immunodeficiency virus (FIV), the principal immunodominant domain (PID) of the transmembrane glycoprotein elicits a strong humoral response in infected hosts. The PID is marked by the presence of two cysteines that delimit a sequence, composed of five to seven amino acids in different lentiviruses, which is highly conserved among isolates of the same lentiviral species. While the conservation of the sequence suggests the presence of functional constraints, the conservation of the immunodominance among divergent lentiviruses raises the hypothesis of a selective advantage for the infecting virus conferred by the host humoral response against this domain. We and others have previously shown that an appropriate structure of the PID is required for the production of a functional envelope. In the present work, we analyzed virological functions and immune reactivity of the envelope after random mutagenesis of the PID of FIV. We obtained nine mutant envelopes which were correctly processed and retained fusogenic ability. Mutation of the two C-terminal residues of the PID sequence between the cysteines in a molecular clone of FIV abolished infectivity. In contrast, three molecular clones containing extensive mutations in the four N-terminal amino acids were infectious. However, the mutations affected PID reactivity with sera from infected cats. Our results suggest that functional constraints, although existent, are not sufficient to account for PID sequence conservation. Such conservation may also result from positive selection by anti-PID antibodies which enhance infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151822      PMCID: PMC191650     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Retrovirus envelope glycoproteins.

Authors:  E Hunter; R Swanstrom
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Analysis of equine humoral immune responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus.

Authors:  Y H Chong; J M Ball; C J Issel; R C Montelaro; K E Rushlow
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  A general model for the transmembrane proteins of HIV and other retroviruses.

Authors:  W R Gallaher; J M Ball; R F Garry; M C Griffin; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Discrimination between antibodies to HIV and to related retroviruses using site-directed serology.

Authors:  E Norrby; G Biberfeld; F Chiodi; A von Gegerfeldt; A Nauclér; E Parks; R Lerner
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

6.  Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy.

Authors:  M B Oldstone; A Tishon; H Lewicki; H J Dyson; V A Feher; N Assa-Munt; P E Wright
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; D Lake; Y Masuho; W M Mitchell; E M Hersh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Follicular dendritic cells and human immunodeficiency virus infectivity.

Authors:  S L Heath; J G Tew; J G Tew; A K Szakal; G F Burton
Journal:  Nature       Date:  1995-10-26       Impact factor: 49.962

9.  Nucleotide sequence and genomic organization of feline immunodeficiency virus.

Authors:  R L Talbott; E E Sparger; K M Lovelace; W M Fitch; N C Pedersen; P A Luciw; J H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  The chemistry of site-directed serology for HIV infections.

Authors:  E Norrby; G Biberfeld; P R Johnson; D E Parks; R A Houghten; R A Lerner
Journal:  AIDS Res Hum Retroviruses       Date:  1989-10       Impact factor: 2.205

View more
  5 in total

1.  Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals.

Authors:  Florestan Desmaris; David Lemaire; Sylvie Ricard-Blum; Benoît Chatrenet; Eric Forest
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

2.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.

Authors:  R Merat; H Raoul; T Leste-Lasserre; P Sonigo; G Pancino
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction.

Authors:  C Sunyach; C Rollier; M Robaczewska; C Borel; L Barraud; A Kay; C Trépo; H Will; L Cova
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Decreased Sensitivity of the Serological Detection of Feline Immunodeficiency Virus Infection Potentially Due to Imported Genetic Variants.

Authors:  Julia Frankenfeld; Theres Meili; Marina L Meli; Barbara Riond; A Katrin Helfer-Hungerbuehler; Eva Bönzli; Benita Pineroli; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2019-07-31       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.